Ligand Pharmaceuticals Incorporated
US ˙ NasdaqGM ˙ US53220K5048

SecurityLGND / Ligand Pharmaceuticals Incorporated
InstitutionBessemer Group Inc
Latest Disclosed Ownership107,859 shares
Latest Disclosed Value $ 21,535
Bessemer Group Inc reports 358.78% increase in ownership of LGND / Ligand Pharmaceuticals Incorporated

On May 6, 2026 - Bessemer Group Inc filed a 13F-HR form disclosing ownership of 107,859 shares of Ligand Pharmaceuticals Incorporated (US:LGND) valued at $21,534,049 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 23,510 shares of Ligand Pharmaceuticals Incorporated. This represents a change in shares of 358.78% during the quarter. The current value of the position is $25,282,150 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 107,859 84,349 358.78 22 425.00 0.0338
2026-02-05 2025-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 23,510 22,764 3,051.47 4 0.0068
2025-11-05 2025-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 746 679 1,013.43 0 0.0002
2025-08-01 2025-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 67 51 318.75 0 0.0000
2025-04-23 2025-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 16 -22 -57.89 0 0.0000
2025-02-13 2024-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 38 38 0 0.0000
2023-11-13 2023-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 0 -17 -100.00 0 0.0000
2023-08-10 2023-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 17 17 0 0.0000
2020-11-12 2020-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 0 -13 -100.00 0 -100.00
2020-08-05 2020-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 13 0 0.00 1 0.00 0.0000
2020-04-30 2020-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 13 -2 -13.33 1 0.00 0.0000
2020-02-04 2019-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 15 1 7.14 1 0.00 0.0000
2019-11-07 2019-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 14 14 1 0.0000
2019-07-19 2019-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 0 -15 -100.00 0 -100.00
2019-05-13 2019-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 15 -6,555 -99.77 2 -99.78 0.0000
2019-05-21 2018-12-31 13F/A-1 LIGAND PHARMACEUTICALS SC 53220K504 6,570 391 6.33 891 -47.46 0.0039
2019-02-12 2018-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 6,570 391 891 0.0039
2018-11-06 2018-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 6,179 179 2.98 1,696 36.44 0.0063
2018-07-25 2018-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 6,000 0 0.00 1,243 25.43 0.0048
2018-05-10 2018-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 6,000 -200 -3.23 991 16.73 0.0039
2018-01-30 2017-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 6,200 2,579 71.22 849 72.21 0.0033
2017-11-03 2017-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 3,621 3,600 17,142.86 493 16,333.33 0.0020
2017-07-27 2017-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 21 0 0.00 3 50.00 0.0000
2017-05-12 2017-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 21 -57 -73.08 2 -75.00 0.0000
2017-02-07 2016-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 78 -5,464 -98.59 8 -98.58 0.0000
2016-11-10 2016-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 5,542 5,451 5,990.11 565 5,036.36 0.0028
2016-08-11 2016-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 91 -76 -45.51 11 -38.89 0.0001
2016-05-11 2016-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 167 -21,727 -99.24 18 -99.24 0.0001
2016-02-12 2015-12-31 13F LIGAND PHARMACEUTICALS SC 53220K504 21,894 0 0.00 2,374 26.61 0.0132
2015-11-16 2015-09-30 13F LIGAND PHARMACEUTICALS SC 53220K504 21,894 21,846 45,512.50 1,875 37,400.00 0.0107
2015-08-14 2015-06-30 13F LIGAND PHARMACEUTICALS SC 53220K504 48 0 0.00 5 25.00 0.0000
2015-06-18 2015-03-31 13F/A-1 LIGAND PHARMACEUTICALS SC 53220K504 48 48 4 0.0000
2015-05-14 2015-03-31 13F LIGAND PHARMACEUTICALS SC 53220K504 48 4
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.